US & Canada
Analysis of federal and state cannabis reform shaping the North American market.
US & Canada · page 2
- Hemp Industry
Is the US Hemp Ban Punishing the Wrong People?
This article was written for Business of Cannabis by Scott Mazza, Co-Founder of Vitality CBD and Certified Headies Uncertainty isn’t what hemp needs right now.
- US & Canada
DEA Selects Only Cannabis Opponents For Crucial June 29 Rescheduling Hearing
In the weeks since cannabis under a state medical licence was moved to Schedule III, US multi-state operators (MSOs) have wasted no time in capitalising on the historic reclassification.
- US & Canada
Mounting Legal Challenges Threaten Hearing to Extend Cannabis Rescheduling to Adult Use
The critical June 29 administrative hearing, set to determine whether the US will extend rescheduling efforts to recreational cannabis, is now set to be a fiercely contested event.
- US & Canada
DOJ Sues TerrAscend for $8.3m in First Known 280E Refund Clawback
The US Department of Justice has filed a federal lawsuit seeking $8.3m plus interest from New Jersey-based cannabis multistate operator TerrAscend (TSX: TSND), in what appears to be the first known instance of the government attempting to recover 280E tax refunds made proactively by a cannabis company.
- US & Canada
‘Not Immediately Compliant’: What the CRS Says America’s Rescheduling Order Actually Delivers
Since President Trump issued an executive order to expedite cannabis rescheduling in December 2025, questions over the legal implications of this route have hung over the industry.
- Industry Trends
DEA’s Schedule III Cannabis Order: A Free-For-All for Telehealth Platforms, or the Perfect Setup for the Entire Industry?
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
- Investment & Finance
The Fight for Cannabis Rescheduling Is Far From Over
Last week’s rescheduling announcement came as a surprise to many, not least to us here at Business of Cannabis.
- Investment & Finance
Federal Agencies Reportedly Told to Prep for Imminent Cannabis Rescheduling Announcement
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
- CBD Market
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost cannabis stocks.
- US & Canada
‘How Does the DEA Plan to Reschedule Without a Judge?’ – Lawmaker Demands Answers on Cannabis Rescheduling Chaos
The White House’s commitment to push through rescheduling has been challenged by a Democratic Senator, who has demanded answers on the administration’s radio silence.
- CBD Market
White House to Meet With Cannabis Industry On Overdue CBD Enforcement Policy
Six weeks after the US Food and Drug Administration (FDA) failed to meet its 90-day deadline to clarify which cannabinoids will be impacted by a controversial incoming ban, the White House has scheduled three meetings with industry executives to discuss the matter.
- Public Markets
US Cannabis Companies Could Finally Get Access to NASDAQ and Financial Services Under New Bill
Bipartisan lawmakers have reintroduced a bill to the House of Representatives that would provide a pathway for cannabis businesses to list on the US stock exchange, accessing the institutional capital they sorely need.
